BioTime (NYSE: BTX) is engaged in developing and commercializing novel therapies based on HyStem cell delivery and pluripotent stem cell technology platforms. The company focuses on regenerative medicine and is developing Renevia, currently in pivotal clinical trial for HIV related facial lipoatrophy; AST-VAC1, a cancer immunotherapy in phase II clinical trials for the treatment of acute myeloid leukemia; OpRegen, in phase I/IIa clinical trial to treat the dry form of age-related macular degeneration; and AST-OPC1, in phase I/II clinical trials for spinal cord injuries. The company also develops Premvia for wound management. For more information, visit the company’s website at www.biotimeinc.com.
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
